---
title: "Iron Deficiency in Heart Failure — Clinical Trials | Amavita Research"
url: https://md.amavitaresearch.com/therapeutic-areas/iron-deficiency-in-heart-failure
canonical: https://www.amavitaresearch.com/therapeutic-areas/iron-deficiency-in-heart-failure
schema_type: MedicalCondition
last_updated: 2026-05-13
---

# Iron Deficiency in Heart Failure — Clinical Trials

Amavita Research enrolls iron-deficient heart failure patients into Phase 3 IV iron repletion trials.

## Currently enrolling

- **IV Ferric Derisomaltose** — Pharmacosmos P-Monofer-CHF-02, Phase 3 iron-deficient HF. https://www.amavitaresearch.com/trials/iv-ferric-derisomaltose

## Patient profile

- Chronic heart failure (HFrEF or HFpEF)
- Iron deficiency: ferritin <100 ng/mL OR 100–300 ng/mL with TSAT <20%
- NYHA class II–IV
- Stable HF medical therapy

## What patients can expect

Free trial-related care including IV iron infusions administered in the on-site infusion suite by trained coordinators under PI supervision. Hemoglobin, ferritin, TSAT monitored throughout.

## Sponsor decision criteria

- On-site IV infusion suite — patients dosed at the site, not referred out
- Same-day ferritin, TSAT, hemoglobin processing
- High prevalence of iron-deficient HF in South Florida population (diabetes co-morbidity)

## Key links

- IV ferric derisomaltose trial detail: https://www.amavitaresearch.com/trials/iv-ferric-derisomaltose
- Patient guide: https://www.amavitaresearch.com/blog/iron-deficiency-heart-failure-clinical-trials-patient-guide
- Site capabilities: https://www.amavitaresearch.com/capabilities
- Contact: https://www.amavitaresearch.com/contact-patient